SplitCore? the latest milestone in ARTES´ vaccine development offer
(PresseBox) - ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the University of Freiburg, Germany. Backbone of this platform is a flexible integration and presentation of foreign antigens on the surface of capsid virus like particles (cVLP), which can be produced in bacteria and yeast.
With its yeast based METAVAX customers an even broader spectrum of service solutions for the development of their specific vaccines.
?With the two potent and versatile platforms, SplitCore and METAVAXveral vaccine candidates manufactured, we are now even stronger positioned to support the development of innovative vaccines.?
SplitCore bases on the technology to split the core or capsid protein of Hepatitis B virus into two parts. These splitted core antigens form efficiently nanoparticles known as capsid virus like particles (cVLP). On the surface of those particles, differently structured proteins can be added with a high degree of freedom and will then be presented highly exposed and hence effective to the immune system.
ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms. ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems, marketing the unique METAVAXterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ARTES Biotechnology is a pharmaceutical contract research&development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms. ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-eVLP) and SplitCore (HepB-cVLP) technology in combination with yeast expression. ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.
Datum: 03.12.2018 - 08:03 Uhr
Sprache: Deutsch
News-ID 1544657
Anzahl Zeichen: 3188
contact information:
Contact person:
Town:
Langenfeld
Phone:
Kategorie:
Handcrafts
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 581 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SplitCore? the latest milestone in ARTES´ vaccine development offer
"
steht unter der journalistisch-redaktionellen Verantwortung von
ARTES Biotechnology GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
